{"id":"NCT01431339","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","briefTitle":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","officialTitle":"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2012-11","completion":"2012-12","firstPosted":"2011-09-09","resultsPosted":"2014-02-12","lastUpdate":"2014-02-12"},"enrollment":739,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Abscess","Wound Infection","Surgical Site Infection","Cellulitis"],"interventions":[{"type":"DRUG","name":"IV Dalbavancin","otherNames":[]},{"type":"DRUG","name":"Vancomycin/Linezolid","otherNames":[]}],"arms":[{"label":"Vancomycin with possible switch to oral linezolid","type":"ACTIVE_COMPARATOR"},{"label":"Dalbavancin","type":"EXPERIMENTAL"}],"summary":"The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.","primaryOutcome":{"measure":"Early Clinical Efficacy","timeFrame":"After 48-72 hours of therapy","effectByArm":[{"arm":"Dalbavancin","deltaMin":285,"sd":null},{"arm":"Vancomycin With Possible Switch to Oral Linezolid","deltaMin":288,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":137,"countries":["United States","Bulgaria","Estonia","Hungary","Israel","Latvia","Lithuania","Romania","Russia","Slovakia","South Africa","South Korea","Taiwan","Ukraine"]},"refs":{"pmids":["34905144","24897082"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":368},"commonTop":["Nausea","Headache","Vomiting","Diarrhoea"]}}